scholarly journals Serum insulin‐like growth factor‐1 concentrations in healthy cats before and after weight gain and weight loss

Author(s):  
Eric Zini ◽  
Elena Salesov ◽  
Anke Willing ◽  
Carlo Palizzotto ◽  
Thomas A. Lutz ◽  
...  
2020 ◽  
Vol 16 (12) ◽  
pp. 1978-1987
Author(s):  
Masahiro Ohira ◽  
Yasuhiro Watanabe ◽  
Takashi Yamaguchi ◽  
Atsuhito Saiki ◽  
Takashi Oshiro ◽  
...  

2015 ◽  
Vol 83 (4) ◽  
pp. 474-477 ◽  
Author(s):  
Roman Dąbrowski ◽  
Marek Szczubiał ◽  
Krzysztof Kostro ◽  
Władysław Wawron ◽  
Jose J. Ceron ◽  
...  

2000 ◽  
Vol 85 (4) ◽  
pp. 1433-1439
Author(s):  
Anthony J. Cleare ◽  
Samantha S. Sookdeo ◽  
Jennifer Jones ◽  
Veronica O’Keane ◽  
John P. Miell

GH deficiency states and chronic fatigue syndrome (CFS) share several characteristics, and preliminary studies have revealed aspects of GH dysfunction in CFS. This study assessed indexes of GH function in 37 medication-free CFS patients without comorbid psychiatric illness and 37 matched healthy controls. We also assessed GH function before and after treatment with low dose hydrocortisone, which has been shown recently to reduce fatigue in CFS. We measured basal levels of serum insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-2 and IGFBP-3 together with 24-h urinary GH excretion. We also performed 2 dynamic tests of GH function: a 100-μg GHRH test and an insulin stress test using 0.15 U/kg BW insulin. There were no differences between patients and controls in basal levels of IGF/IGFBP or in urinary GH excretion. GH responses to both the GHRH test and the insulin stress test were no different in patients and controls. CFS patients did have a marginally reduced suppression of IGFBP-1 during the insulin stress test. Hydrocortisone treatment had no significant effect on any of these parameters. There is no evidence of GH deficiency in CFS. At the doses used, hydrocortisone treatment appears to have little impact on GH function.


2002 ◽  
Vol 75 (1) ◽  
pp. 41-47
Author(s):  
C. Gazzola ◽  
M. R. Jeffery ◽  
D. H. White ◽  
R. A. Hill ◽  
D. J. Reid

AbstractMale beef calves in northern Australia are generally castrated under 6 months of age as an aid to management of animal behaviour and for the purpose of producing sufficiently fat carcasses at slaughter. It is also common for beef producers to administer hormone growth promotants, such as oestradiol, to increase the growth rates of steers at pasture. This experiment tested the hypothesis that delaying castration by 9 months would produce an increase in growth rate for the period while the cattle are retained as bulls without compromising management of animal behaviour. Bulls of three genotypes were castrated at 7 months or 16 months of age and half were treated with oestradiol after castration. Body weight (BW) and serum insulin-like growth factor-1 concentrations (IGF-1) were measured and behaviour was observed before and after the 16 month castration. At both 7 and 16 months of age, surgical castration of bulls caused no animal welfare problems. BW gain was affected by genotype with Bos taurus types having a lower BW gain than Bos indicus and F1-cross cattle. IGF-1 was similarly affected by genotype. Oestradiol treatment increased growth of the steers (early castrates) during the 9 months between castration times compared with non-implanted steers and bulls. Oestradiol implanted steers had similar BW gain from the late castration to slaughter, regardless of age at castration, which was greater than non-implanted early castrates which, in turn, was greater than the late castrates. Similar differences were observed for IGF-1 concentrations. Behaviour was not affected by genotype, oestradiol treatment or age of castration but this may have been an artefact of the design where all treatment groups were grazed together. Although delayed castration resulted in no behavioural or management problems, it did not produce a commercially useful increase in growth rate.


Sign in / Sign up

Export Citation Format

Share Document